DexCom (NASDAQ:DXCM) Given New $85.00 Price Target at Wells Fargo & Company

DexCom (NASDAQ:DXCM) had its price target decreased by Wells Fargo & Company from $93.00 to $85.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the medical device company’s stock. Wells Fargo & Company‘s target price would indicate a potential upside of 19.99% from the stock’s previous close.

Several other equities analysts have also issued reports on the company. Truist Financial reaffirmed a “buy” rating and set a $82.00 price target (down previously from $94.00) on shares of DexCom in a research note on Monday, November 3rd. Evercore began coverage on DexCom in a research note on Tuesday, November 25th. They set an “in-line” rating and a $68.00 target price for the company. Leerink Partners reaffirmed an “outperform” rating and issued a $92.00 price target on shares of DexCom in a research note on Tuesday, December 16th. Barclays restated an “underweight” rating and set a $72.00 price objective on shares of DexCom in a report on Friday. Finally, Sanford C. Bernstein reaffirmed an “outperform” rating and issued a $86.00 target price (up from $84.00) on shares of DexCom in a research note on Friday, January 9th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and a consensus target price of $85.23.

DexCom Trading Up 8.9%

Shares of NASDAQ DXCM opened at $70.84 on Friday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.38 and a current ratio of 1.56. The stock has a market cap of $27.63 billion, a price-to-earnings ratio of 38.74, a PEG ratio of 1.22 and a beta of 1.49. The business has a 50 day simple moving average of $68.94 and a 200 day simple moving average of $69.88. DexCom has a 52 week low of $54.11 and a 52 week high of $93.25.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.03. The business had revenue of $1.26 billion during the quarter, compared to analysts’ expectations of $1.25 billion. DexCom had a return on equity of 30.65% and a net margin of 15.96%.DexCom’s quarterly revenue was up 13.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.45 EPS. On average, research analysts predict that DexCom will post 2.03 earnings per share for the current fiscal year.

Institutional Investors Weigh In On DexCom

A number of institutional investors have recently added to or reduced their stakes in the business. Trust Co. of Vermont lifted its stake in DexCom by 14.8% in the fourth quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock valued at $74,000 after buying an additional 145 shares during the period. CVA Family Office LLC boosted its holdings in DexCom by 48.5% during the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after acquiring an additional 147 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of DexCom by 2.5% in the 3rd quarter. GAMMA Investing LLC now owns 7,043 shares of the medical device company’s stock worth $474,000 after acquiring an additional 169 shares in the last quarter. IFP Advisors Inc lifted its position in shares of DexCom by 24.7% during the third quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock valued at $61,000 after purchasing an additional 178 shares in the last quarter. Finally, Inspire Investing LLC boosted its holdings in DexCom by 6.1% during the third quarter. Inspire Investing LLC now owns 3,139 shares of the medical device company’s stock worth $211,000 after purchasing an additional 180 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

DexCom News Summary

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Mizuho raised its price target to $90 and upgraded DexCom to “Outperform,” implying ~38% upside from the $65.08 reference price, signaling stronger analyst conviction. Mizuho raises target to $90 (Benzinga)
• Positive Sentiment: BTIG reaffirmed a “Buy” rating with an $85 target (~31% upside), reinforcing the street’s favorable view after the quarter. BTIG reaffirms Buy $85 (Benzinga)
• Positive Sentiment: Q4 results beat expectations: EPS $0.68 vs $0.65 estimate and revenue $1.26B vs $1.25B estimate; revenue rose ~13.1% YoY and management cited strong demand for continuous glucose monitors — the primary near-term catalyst for revenue and growth. Dexcom beats quarterly estimates (Reuters)
• Positive Sentiment: Product/engagement update: a Stelo AI upgrade aims to deepen consumer metabolic-health engagement — a potential long-term revenue and retention positive if adoption accelerates. Stelo AI upgrade (Yahoo Finance)
• Neutral Sentiment: Earnings call materials and transcripts are available (slides, press release, call transcripts), providing detail on guidance and product cadence — useful for confirming whether upside is sustainable. BusinessWire press release
• Neutral Sentiment: Multiple transcripts and write-ups (Seeking Alpha, Yahoo Finance, Zacks) cover the call—investors should review management commentary on 2026 outlook and margin trajectory to assess sustainability of the beats. Earnings call transcript (Seeking Alpha)
• Neutral Sentiment: Short-interest data reported shows zeros/NaN for February — this appears to be erroneous data and shouldn’t be interpreted as meaningful market positioning. (Internal report)
• Negative Sentiment: Despite the recent beat and analyst bullishness, DexCom has underperformed the broader market over the past year and still trades near levels below its 12‑month high; valuation remains elevated (P/E ~36), so upside depends on sustained revenue/margin improvement and guidance. Analyst targets and context (Barchart)

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.